The Schall Law Firm has launched an investigation into TriSalus Life Sciences, Inc. for potential securities law violations. The investigation centers on whether the company made false or misleading statements or failed to disclose material information to investors. TriSalus reported its first-quarter financial results on May 12, 2026, revealing a year-over-year quarterly revenue decline of more than 2.9% and a cut to its full-year revenue guidance. The company attributed the revision to lower first-quarter revenues from commercial expansion and a delay in FDA clearance for its TriNav Advance device, which is now running approximately five months past the 30-day MDUFA review goal.
TriSalus Life Sciences Inc.Investigation for securities law violations and delayed FDA clearance for TriNav Advance device.